Voyager Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Voyager Therapeutics yıllık ortalama 34.4% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.1% annual. Gelirler growing yılda ortalama 9.4% oranında artmaktadır. Voyager Therapeutics'in özkaynak karlılığı 7.8% ve net marjı 15.8%'dir.

Anahtar bilgiler

34.4%

Kazanç büyüme oranı

33.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	9.4%
Özkaynak getirisi	7.8%
Net Marj	15.8%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Nov 18

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12

Voyager Does A Reboot After First Generation Failures

Mar 25

Gelir ve Gider Dağılımı

Voyager Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:VYGR Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	164	26	37
30 Jun 24	144	9	37
31 Mar 24	119	-3	35
31 Dec 23	250	132	36
30 Sep 23	158	52	34
30 Jun 23	195	96	33
31 Mar 23	191	99	32
31 Dec 22	41	-46	31
30 Sep 22	71	-17	31
30 Jun 22	31	-60	32
31 Mar 22	32	-71	35
31 Dec 21	37	-71	37
30 Sep 21	16	-93	37
30 Jun 21	132	18	37
31 Mar 21	160	39	35
31 Dec 20	171	37	35
30 Sep 20	197	40	37
30 Jun 20	100	-61	37
31 Mar 20	117	-41	37
31 Dec 19	104	-44	36
30 Sep 19	74	-54	40
30 Jun 19	55	-59	38
31 Mar 19	12	-96	36
31 Dec 18	8	-88	34
30 Sep 18	12	-78	26
30 Jun 18	11	-81	24
31 Mar 18	10	-74	22
31 Dec 17	10	-71	20
30 Sep 17	6	-74	18
30 Jun 17	8	-59	16
31 Mar 17	11	-50	15
31 Dec 16	14	-40	13
30 Sep 16	17	-34	13
30 Jun 16	18	-32	12
31 Mar 16	20	-30	12
31 Dec 15	17	-38	10
30 Sep 15	12	-35	8
30 Jun 15	7	-32	7
31 Mar 15	3	-30	6
31 Dec 14	0	-18	5

Kaliteli Kazançlar: VYGR yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: VYGR 'nin mevcut net kar marjları (15.8%) geçen yılın (33%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VYGR son 5 yılda karlı hale geldi ve kazançlarını yıllık 34.4% oranında artırdı.

Büyüme Hızlandırma: VYGR 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: VYGR geçtiğimiz yıl negatif kazanç büyümesine ( -50.5% ) sahipti ve bu da onu Biotechs sektör ortalamasıyla ( 16.6% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: VYGR 'nin Özsermaye Getirisi ( 7.8% ) düşük olarak değerlendiriliyor.

Voyager Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Recent updates

Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026

Investor sentiment deteriorates as stock falls 23%

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 19%

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Investor sentiment improves as stock rises 20%

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Consensus revenue estimates increase by 29%

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Consensus revenue estimates fall by 21%

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Investor sentiment improves as stock rises 18%

President recently sold US$97k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New minor risk - Share price stability

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold US$95k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Chief Science Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 25%

Price target increased by 9.8% to US$11.17

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President recently sold US$58k worth of stock

Chief Operating Officer recently sold US$126k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$8.20

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Consensus revenue estimates increase by 170%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target